US Patent Issued to Hangzhou Innogate Pharma on July 15 for "Heterocyclic comipound as CDK-HDAC dual pathway inhibitor" (Chinese Inventors)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,358,911, issued on July 15, was assigned to Hangzhou Innogate Pharma Co. Ltd. (Zhejiang, China).

"Heterocyclic comipound as CDK-HDAC dual pathway inhibitor" was invented by Hancheng Zhang (Zhejiang, China), Xiangyang Ye (Zhejiang, China) and Xin Cheng (Zhejiang, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides compounds of formula (I) as shown below, as well as pharmaceutically acceptable salts, hydrates or solvates thereof. The invention also provides pharmaceutical compositions of these compounds, methods for their preparation, and their use in the treatment of diseases and disorders (including cancers)."

The patent was fil...